Gut Bacteria Produce a Fatty Acid That Slows Artery Plaque Buildup in Mice
A bacterial fatty acid lowered cholesterol and artery plaque in mice, revealing a potential treatment pathway—not a proven supplement benefit.
Summary
Gut bacteria may help protect arteries by producing a fatty acid that changes how the liver handles cholesterol. Researchers found that Bacteroides uniformis was more abundant in healthy adults than in adults with atherosclerotic cardiovascular disease. Giving this bacterium to male mice prone to artery plaque buildup lowered cholesterol and reduced plaque compared with untreated controls. The team traced the effect to pentadecanoic acid, also called C15:0. This compound reduced cholesterol production in the liver and increased its ability to remove cholesterol from blood. Purified C15:0 reduced plaque burden by about half in another mouse experiment, although the article describes a smaller effect than atorvastatin. These findings suggest a potential treatment pathway, not a reason to start supplements or stop medication. Human benefits, safety, and effective dosing remain unproven.
Detailed Summary
Gut bacteria may influence artery health by producing compounds that change how the liver handles cholesterol. A study summarized by Lifespan.io identifies pentadecanoic acid, also called C15:0, as a promising candidate. In mice prone to atherosclerosis, this fatty acid reduced cholesterol levels and arterial plaque buildup, suggesting a possible avenue for cardiovascular treatment.
Researchers first analyzed human gut microbiome data and found that Bacteroides uniformis was associated with healthy controls rather than cardiovascular disease. Giving this bacterium to male mice lacking the Apoe gene for twelve weeks reduced plaque burden, LDL cholesterol, total cholesterol, and triglycerides. HDL cholesterol did not change significantly, and plaques contained fewer inflammatory immune cells.
The liver appeared central to these benefits. Treatment reduced cholesterol production and increased receptors that remove LDL particles from blood, alongside activation of the cholesterol regulator SREBP2. Disabling LDL receptors specifically in the liver eliminated the benefits. Dead bacteria were ineffective, while an extract of bacterial culture fluid worked, implicating a substance released by living bacteria.
Researchers identified that substance as C15:0. Eight weeks of purified C15:0 reduced plaque burden by about half compared with controls and lowered total and LDL cholesterol. Plaque macrophages and systemic inflammatory markers also declined. Atorvastatin served as an established treatment comparator; the article describes the fatty acid's effect as smaller than the drug's. Both treatments used the same experimental dosing schedule.
These findings do not justify taking C15:0 supplements or replacing prescribed cholesterol medication. Human microbiome associations cannot establish causation, and results from genetically susceptible male mice may not translate to women or men. Because baseline plaque was not measured, the experiments support slower disease progression, not proven reversal. The supplied article ends mid-sentence, so the primary study should be checked for complete experimental methods, safety data, sample sizes, and the full comparison with atorvastatin.
Key Findings
- Twelve weeks of Bacteroides uniformis treatment reduced arterial plaque, LDL cholesterol, total cholesterol, and triglycerides in atherosclerosis-prone male mice.
- Purified C15:0 reduced plaque burden by about 50% versus controls after eight weeks; this does not demonstrate plaque reversal.
- Removing liver LDL receptors eliminated the bacterium's benefits, identifying cholesterol clearance as essential to its protective effect.
- Human microbiome findings were observational; they do not establish that the bacterium prevents cardiovascular disease in humans.
- Do not replace prescribed cholesterol treatment with C15:0 supplements based on these mouse experiments.
Methodology
This is a research news summary from Lifespan.io describing a study reportedly published in Nature. The evidence combines observational human microbiome data with controlled mouse experiments, liver-specific gene disruption, and tests of bacterial products; the primary paper was not supplied for verification.
Study Limitations
The supplied text is truncated and omits sample sizes, detailed statistics, safety findings, and the complete atorvastatin comparison. Intervention results came from genetically susceptible male mice, while human findings were observational; absent baseline plaque measurements also prevent claims of disease reversal.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: